4.6 Article

Race, Interleukin-6, TMPRSS6 Genotype, and Cardiovascular Disease in Patients With Chronic Kidney Disease

期刊

出版社

WILEY
DOI: 10.1161/JAHA.122.025627

关键词

anemia; cytokines; genetics; inflammation; mortality; progression of chronic kidney disease

资金

  1. National Institute of Diabetes and Digestive and Kidney Diseases [U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, U24DK060990]
  2. Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award National Institutes of Health/National Center for Advancing Translational Sciences [UL1TR000003]
  3. Johns Hopkins University [UL1 TR-000424]
  4. University of Maryland [GCRC M01 RR-16500]
  5. Clinical and Translational Science Collaborative of Cleveland
  6. National Center for Advancing Translational Sciences component of the National Institutes of Health [UL1TR000439]
  7. National Institutes of Health Roadmap for Medical Research, Michigan Institute for Clinical and Health Research [UL1TR000433]
  8. University of Illinois at Chicago Clinical and Translational Science Awards [UL1RR029879]
  9. Tulane Centers of Biomedical Research Excellence for Clinical and Translational Research in Cardiometabolic Diseases [P20 GM109036]
  10. Kaiser Permanente National Institutes of Health/National Center for Research Resources [UCSF-CTSI UL1 RR-024131]
  11. Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque [NM R01DK119199]
  12. Corvidia Therapeutics
  13. National Institutes of Health [1 R01DK125256, R01 DK073665-01A1, 1U01DK099924-01, 1U01DK099914-01]
  14. Relypsa

向作者/读者索取更多资源

Differences in death rate and cardiovascular disease between Black and White patients with chronic kidney disease can be explained by sociocultural factors, comorbidities, genetics, and inflammation. Plasma IL-6 and TMPRSS6 genotype are also determinants of CVD and mortality.
Background Differences in death rate and cardiovascular disease (CVD) between Black and White patients with chronic kidney disease is attributed to sociocultural factors, comorbidities, genetics, and inflammation. Methods and Results We examined the interaction of race, plasma IL-6 (interleukin-6), and TMPRSS6 genotype as determinants of CVD and mortality in 3031 Chronic Renal Insufficiency Cohort study participants. The primary outcomes were all-cause mortality and a composite of incident myocardial infarction, peripheral artery disease, stroke, and heart failure. During the median follow-up of 10 years, Black patients with chronic kidney disease experienced a significantly higher mortality (34% versus 26%) and CVD composite (41% versus 28%) compared with White patients. After adjustment, TMPRSS6 genotype did not associate with the outcomes. The adjusted hazard ratio for mortality (4.11 [2.48-6.80], P<0.001) and CVD composite (2.52 [1.96-3.24], P<0.001) were higher for the highest versus lowest IL-6 quintile. The adjusted hazards for death per 1-quintile increase in IL-6 in White and Black individuals were 1.53 (1.42-1.64) versus 1.29 (1.20-1.38) (P<0.001), respectively. For CVD composite they were 1.61 (1.50-1.74) versus 1.30 (1.22-1.39) (P<0.001), respectively. In Cox proportional hazard models that included IL-6, there was no longer a racial disparity for death (1.01 [0.87-1.16], P=0.92), but significant unexplained mediation remained for CVD (1.24 [1.07-1.43]; P=0.004). Path models that included IL-6, diabetes, and urine albumin to creatinine ratio were able to identify variables responsible for racial disparity in mortality and CVD. Conclusions Racial differences in mortality and CVD among patients with chronic kidney disease could be explained by good-fitting path models that include selected mediator variables including diabetes and plasma IL-6.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据